<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03860220</url>
  </required_header>
  <id_info>
    <org_study_id>STAROS</org_study_id>
    <nct_id>NCT03860220</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin</brief_title>
  <official_title>A Multi-center, Randomized, Parallel Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin in Patients With Dyslipidemia and Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hyo-Soo Kim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study was to assess the efficacy and safety of FDC therapy with triple
      therapy of Telmisartan 40 mg/Amlodipine 5 mg/Rosuvastatin 10mg in Korean patients with both
      hypertension and dyslipidemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients were randomly assigned to 2 groups: (1) Triple therapy (40mg of telmisartan and 5mg
      of amlodipine and 10mg of rosuvastatin); (2) Dual therapy (5mg of amlodipine and 10mg of
      atorvastatin). After 8 weeks of treatment, the change in mean sitting systolic blood pressure
      (MSSBP) and the percent change in LDL-C between 2 group, will be compared.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent changes in mean sitting systolic blood pressure (MSSBP)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percent changes in MSSBP from baseline after 8 weeks of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent changes in LDL-C</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percent changes in LDL-C from baseline after 8 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent changes in LDL-C</measure>
    <time_frame>4 weeks</time_frame>
    <description>Percent changes in LDL-C from baseline after 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent changes in TC</measure>
    <time_frame>4, 8weeks</time_frame>
    <description>Percent changes in TC from baseline after 4 and 8 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent changes in TG</measure>
    <time_frame>4, 8weeks</time_frame>
    <description>Percent changes in TG from baseline after 4 and 8 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent changes in HDL-C</measure>
    <time_frame>4, 8weeks</time_frame>
    <description>Percent changes in HDL-C from baseline after 4 and 8 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent changes in Non-HDL-C</measure>
    <time_frame>4, 8weeks</time_frame>
    <description>Percent changes in Non-HDL-C from baseline after 4 and 8 weeks of treatement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent changes in Apo B</measure>
    <time_frame>4, 8weeks</time_frame>
    <description>Percent changes in Apo B from baseline after 4 and 8 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent changes in Apo A-I</measure>
    <time_frame>4, 8weeks</time_frame>
    <description>Percent changes in Apo A-I from baseline after 4 and 8 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent changes in LDL-C/HDL-C ratio</measure>
    <time_frame>4, 8weeks</time_frame>
    <description>Percent changes in LDL-C/HDL-C from baseline after 4 and 8 weeks of treatement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent changes in Apo B/Apo A-I ratio</measure>
    <time_frame>4, 8weeks</time_frame>
    <description>Percent changes in Apo B/Apo A-I from baseline after 4 and 8 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent changes in hs-CRP</measure>
    <time_frame>4, 8weeks</time_frame>
    <description>Percent changes in hs-CRP from baseline after 4 and 8 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients achieving treatment goal for blood pressure and LDL-C</measure>
    <time_frame>8 weeks</time_frame>
    <description>The percentage of patients achieving treatment goal for blood pressure and LDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in mean sitting systolic/diastolic blood pressure</measure>
    <time_frame>4, 8weeks</time_frame>
    <description>Changes in mean sitting systolic/diastolic blood pressure after 4 and 8 weeks of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">304</enrollment>
  <condition>Hypertension</condition>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>NEWSTATIN TS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Triple therapy (Telmisartan + Amlodipine + Rosuvastatin 40/5/10mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CADUET</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dual therapy (Amlodipine + Atorvastatin 5/10mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NEWSTATIN TS</intervention_name>
    <description>Wash out/run in period with Amlodipine 5mg for 6 weeks and then treatment with triple therapy (Newstatin TS 40/5/10mg) ; 1 tab qd for 8 weeks</description>
    <arm_group_label>NEWSTATIN TS</arm_group_label>
    <other_name>Newstatin TS 40/5/10mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CADUET</intervention_name>
    <description>Wash out/run in period with Amlodipine 5mg for 6 weeks and then treatment with dual therapy (Caduet 5/10mg) ; 1 tab qd for 8 weeks</description>
    <arm_group_label>CADUET</arm_group_label>
    <other_name>Caduet 5/10mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  145 mmHg ≤ msSBP ≤ 190 mmHg

          -  Triglycerides &lt; 500 mg/dL

          -  LDL-C ≤ 250 mg/dL

        Exclusion Criteria:

          -  sSBP ≥ 20mmHg and sDBP ≥ 10mmHg

          -  symptomatic orthostatic hypotension and secondary/iatrogenic hypertension and
             dyslipidemia

          -  history of moderate to severe cerebral ischemia, cerebral hemorrhage, transient
             ischemic attack, myocardial infarction, or unstable angina in the past 6 months;
             severe heart failure (New York Heart Association functional class III and IV)

          -  hypersensitivity to telmisartan or rosuvastatin

          -  history of angioedema after treatment with angiotensin-converting enzyme inhibitors or
             ARBs; creatinine phosphokinase levels ≥3 times the upper limit of normal

          -  estimated glomerular filtration rate ≤30 mL/min; aspartate aminotransferase and
             alanine aminotransferase levels ≥3 times the upper limit of normal

          -  potassium levels &gt;5.5 mmol/L; or any diseases that could affect the results of the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo-Soo Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hak Seung Lee</last_name>
    <phone>82-10-3166-8399</phone>
    <email>cardiolee@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuehee Yeom</last_name>
    <email>turtree@naver.com</email>
  </overall_contact_backup>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2019</study_first_posted>
  <last_update_submitted>February 28, 2019</last_update_submitted>
  <last_update_submitted_qc>February 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Hyo-Soo Kim</investigator_full_name>
    <investigator_title>Director, Coronary Intervention &amp; Transcatheter Aortic Valve Implantation</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine, atorvastatin drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

